Skip to main content
OpenTrials
Completed

NCT Number: NCT02279966

Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

To assess the efficacy of acute treatment with 10 mg/day vortioxetine versus placebo on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning, attention) in working patients with major depressive disorder (MDD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

EE001, Tallinn, Estonia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™) recurrent major depressive disorder (MDD) (classification 296.3x).
  • The patient has a MADRS total score ≥26.
  • The patient has had the current major depressive episode (MDE) for ≥3 months.
  • The patient is aged ≥18 and ≤65 years.
  • The patient is employed full or part-time (defined as minimum 50% full time working hours per week). Part time work should not be due to a medical or mental illness other than MDD.
  • The patient has been in the current job/position for at least 3 months.
  • The patient has no plans to change jobs or retire within treatment period.
  • The patient is not on a sick leave, and at the Screening and Randomisation Visits, there are no plans to send the patient on a sick leave.
  • The patient is not receiving disability benefits.

Exclusion criteria

  • The patient has a score ≥70 on the DSST (number of correct symbols) at the Baseline Visit.
  • The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient has a history of lack of response to previous adequate treatment with vortioxetine or paroxetine.
  • The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using MINI.
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of current episode (DSM-IV-TR™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, or histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol-defined inclusion and exclusion criteria may apply.

Treatment and study plan

Vortioxetine 10 mg

Drug

Other names: Brintellix®, Lu AA21004

Paroxetine 20 mg

Drug

Placebo

Drug

Primary outcomes

  1. Change in Digit Symbol Substitution Test (DSST): number of correct symbols

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Trail Making Test (TMT) score: TMT-A; speed of processing

    Time frame: Baseline to Week 8

  2. Change in TMT-B; executive functioning

    Time frame: Baseline to Week 8

  3. Change in reaction time score: Choice Reaction Time (CRT); attention

    Time frame: Baseline to Week 8

  4. Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed)

    Time frame: Baseline to Week 8

  5. Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning

    Time frame: Baseline to Week 8

  6. Change in STROOP: congruent score; speed of processing

    Time frame: Baseline to Week 8

  7. Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score

    Time frame: Baseline to Week 8

  8. Change in Montgomery and Asberg Depression Rating Scale (MADRS) total score

    Time frame: Baseline to Week 8

  9. Change in Clinical Global Impression - Severity of Illness (CGI-S)

    Time frame: Baseline to Week 8

  10. Clinical Global Impression - Global Improvement (CGI-I) score

    Time frame: Week 8

  11. Change in the Functioning Assessment Short Test (FAST) total score

    Time frame: Baseline to Week 8

  12. Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score

    Time frame: Baseline to Week 8

Sponsors and collaborators

Lead sponsor

H. Lundbeck A/S

Industry

Registry information

Official study title

An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Oct 31, 2014
Registry last updated
Feb 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.